The END Fund is the world's first private philanthropic initiative to combat the five most common neglected tropical diseases (NTDs) that, together, cause up to 90% of the NTD burden in sub-Saharan Africa. Supported by a group of global philanthropists, the END Fund provides financing for nationwide disease control initiatives, creating new programs, supplementing existing ones, and using leveraged funds to extend and deepen the impact.
The END Fund provides exceptional return on investment by harnessing the highly scalable impact of low-cost mass drug administrations.
The END Fund is dedicated to controlling and eliminating neglected tropical diseases. NTDs are diseases of poverty that debilitate, blind, disfigure and cause early death to the world’s poorest people. They are a group of parasitic and bacterial infectious diseases that thrive in conditions of rural poverty, where children and adults do not have access to clean water and basic sanitation.
Over 1.5 billion people globally are affected by one or more of the most common NTDs, including 875 million children. The END Fund focuses on tackling the five most prevalent NTDs: intestinal worms, schistosomiasis, lymphatic filariasis, trachoma, and river blindness - all of which can be treated by medicines generously donated by pharmaceutical companies for national mass drug administration programs.
- Mobilizing and directing resources to where they can have maximum impact, with a special emphasis on Africa.
- Advocating for innovative, integrated and cost-effective NTD programs.
- Facilitating private sector engagement in the movement to address the devastating effects of NTDs
Their Strategy on the Ground
The END Fund, in collaboration with government partners and non-governmental organizations on the ground, treats NTDs by following a proven implementation model that is tailored to meet the needs of individual countries. Successful implementation involves understanding the scale of the problem and designing a robust MDA campaign targeted to reach and treat the right people. It is a process that catalyzes resources, builds capacity among health professionals, and mobilizes communities to distribute medicines for maximum impact at minimal cost.
1. Secure Funding
8. Mobilize and Treat
Where is The END Fund